KR20070050861A - ４-비아릴일-１-페닐아제티딘-２-온 - Google Patents
４-비아릴일-１-페닐아제티딘-２-온 Download PDFInfo
- Publication number
- KR20070050861A KR20070050861A KR1020067011344A KR20067011344A KR20070050861A KR 20070050861 A KR20070050861 A KR 20070050861A KR 1020067011344 A KR1020067011344 A KR 1020067011344A KR 20067011344 A KR20067011344 A KR 20067011344A KR 20070050861 A KR20070050861 A KR 20070050861A
- Authority
- KR
- South Korea
- Prior art keywords
- fluorophenyl
- lower alkyl
- hydroxypropyl
- azetidin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(CCC(C(*1c2ccccc2)c2ccccc2)C1=O)c1ccccc1 Chemical compound *C(CCC(C(*1c2ccccc2)c2ccccc2)C1=O)c1ccccc1 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- SRWNNIVTBXXCMI-ATNBEAFSSA-N CC(C)(C)[Si](C)(C)O[C@@H](CC[C@H]([C@@H](c(c(OC(C)=O)c1)ccc1[Br]=C)N1c2ccccc2)C1=O)c(cc1)ccc1F Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CC[C@H]([C@@H](c(c(OC(C)=O)c1)ccc1[Br]=C)N1c2ccccc2)C1=O)c(cc1)ccc1F SRWNNIVTBXXCMI-ATNBEAFSSA-N 0.000 description 1
- KQFJQNGJKOXDHK-UHFFFAOYSA-N O=C(C(C1c(cc2)ccc2-c2ccccc2)[U]c2ccccc2)N1c1ccccc1 Chemical compound O=C(C(C1c(cc2)ccc2-c2ccccc2)[U]c2ccccc2)N1c1ccccc1 KQFJQNGJKOXDHK-UHFFFAOYSA-N 0.000 description 1
- LEQVFNWSOPWYDQ-JKXZAXKXSA-N OC(CCC([C@@H](c(cc1)ccc1OS(C(F)(F)F)(=O)=O)N1c(cc2)ccc2F)C1O)c(cc1)ccc1F Chemical compound OC(CCC([C@@H](c(cc1)ccc1OS(C(F)(F)F)(=O)=O)N1c(cc2)ccc2F)C1O)c(cc1)ccc1F LEQVFNWSOPWYDQ-JKXZAXKXSA-N 0.000 description 1
- BAOIFGKFUOVKMD-VTLFHKLASA-N OC(CCC([C@@H](c(nc1)ccc1Br)N1c2ccccc2)C1=O)c(cc1)ccc1F Chemical compound OC(CCC([C@@H](c(nc1)ccc1Br)N1c2ccccc2)C1=O)c(cc1)ccc1F BAOIFGKFUOVKMD-VTLFHKLASA-N 0.000 description 1
- RBMIEKTYSGNOCW-HSIAWCKKSA-N OCCC([C@@H]([C@H]1O)O)OC([C@H](c2cccc(-c3ccc([C@H](C(CCC(c(cc4)ccc4F)O)C4=O)N4c4ccccc4)cc3)c2)O)[C@H]1O Chemical compound OCCC([C@@H]([C@H]1O)O)OC([C@H](c2cccc(-c3ccc([C@H](C(CCC(c(cc4)ccc4F)O)C4=O)N4c4ccccc4)cc3)c2)O)[C@H]1O RBMIEKTYSGNOCW-HSIAWCKKSA-N 0.000 description 1
- KEGPPNGRTJGVBB-PZFKOMAXSA-N O[C@@H](CC[C@H]([C@@H](c(c(O)c1)ccc1-c(cccc1)c1O)N1c2ccccc2)C1=O)c1ccccc1F Chemical compound O[C@@H](CC[C@H]([C@@H](c(c(O)c1)ccc1-c(cccc1)c1O)N1c2ccccc2)C1=O)c1ccccc1F KEGPPNGRTJGVBB-PZFKOMAXSA-N 0.000 description 1
- XUQGIZSRVSEBNV-LKOMEEOBSA-N O[C@@H](CC[C@H]([C@@H](c(cc1)ccc1-c1cc(O)ccc1)N1c2ccc(CCCC[N]3(CC4)CCC4CC3)cc2)C1=O)c1ccccc1 Chemical compound O[C@@H](CC[C@H]([C@@H](c(cc1)ccc1-c1cc(O)ccc1)N1c2ccc(CCCC[N]3(CC4)CCC4CC3)cc2)C1=O)c1ccccc1 XUQGIZSRVSEBNV-LKOMEEOBSA-N 0.000 description 1
- JEKVBHFAVXLUIU-UHFFFAOYSA-N Oc1cc(-c2ccccc2)ccc1C(C(C1=O)[U]c2ccccc2)N1c1ccccc1 Chemical compound Oc1cc(-c2ccccc2)ccc1C(C(C1=O)[U]c2ccccc2)N1c1ccccc1 JEKVBHFAVXLUIU-UHFFFAOYSA-N 0.000 description 1
- SYGXABIKEZBFEJ-JCHVILAISA-N Oc1ccccc1-c1ccc([C@H](C(CCC(C(C=C2)=CCC2F)=O)C2=O)N2c(cc2)ccc2F)cc1 Chemical compound Oc1ccccc1-c1ccc([C@H](C(CCC(C(C=C2)=CCC2F)=O)C2=O)N2c(cc2)ccc2F)cc1 SYGXABIKEZBFEJ-JCHVILAISA-N 0.000 description 1
- FTJFTZVBCNJNGS-CVWZLOPKSA-N [O-][N+](c1cc(-c2ccc([C@H](C(CC[C@@H](c(cc3)ccc3F)O)C3=O)N3c(cc3)ccc3F)cc2)ccc1)=O Chemical compound [O-][N+](c1cc(-c2ccc([C@H](C(CC[C@@H](c(cc3)ccc3F)O)C3=O)N3c(cc3)ccc3F)cc2)ccc1)=O FTJFTZVBCNJNGS-CVWZLOPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51869803P | 2003-11-10 | 2003-11-10 | |
| US60/518,698 | 2003-11-10 | ||
| US54957704P | 2004-03-03 | 2004-03-03 | |
| US60/549,577 | 2004-03-03 | ||
| US59252904P | 2004-07-30 | 2004-07-30 | |
| US60/592,529 | 2004-07-30 | ||
| US61400504P | 2004-09-28 | 2004-09-28 | |
| US60/614,005 | 2004-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070050861A true KR20070050861A (ko) | 2007-05-16 |
Family
ID=34596124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067011344A Ceased KR20070050861A (ko) | 2003-11-10 | 2004-11-10 | ４-비아릴일-１-페닐아제티딘-２-온 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7320972B2 (enExample) |
| EP (1) | EP1682499B1 (enExample) |
| JP (1) | JP2007520453A (enExample) |
| KR (1) | KR20070050861A (enExample) |
| AT (1) | ATE369335T1 (enExample) |
| AU (1) | AU2004288822A1 (enExample) |
| BR (1) | BRPI0416361A (enExample) |
| CA (1) | CA2545058A1 (enExample) |
| CY (1) | CY1106982T1 (enExample) |
| DE (1) | DE602004008100T2 (enExample) |
| DK (1) | DK1682499T3 (enExample) |
| EA (1) | EA010026B1 (enExample) |
| ES (1) | ES2291974T3 (enExample) |
| IL (1) | IL175414A0 (enExample) |
| MA (1) | MA28216A1 (enExample) |
| MX (1) | MXPA06005106A (enExample) |
| NO (1) | NO20062665L (enExample) |
| NZ (1) | NZ546940A (enExample) |
| PL (2) | PL1682499T3 (enExample) |
| PT (1) | PT1682499E (enExample) |
| WO (1) | WO2005047248A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| EP1682499B1 (en) * | 2003-11-10 | 2007-08-08 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
| WO2005061452A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| WO2006086562A2 (en) * | 2005-02-09 | 2006-08-17 | Microbia, Inc. | Phenylazetidinone derivatives |
| WO2006102674A2 (en) * | 2005-03-24 | 2006-09-28 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| EP1877067A1 (en) * | 2005-04-26 | 2008-01-16 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| WO2006121861A2 (en) * | 2005-05-05 | 2006-11-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| TW200726746A (en) | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
| CA2608108A1 (en) * | 2005-05-09 | 2006-11-16 | Microbia, Inc. | Organometal benzenephosphonate coupling agents |
| BRPI0608970A2 (pt) * | 2005-05-11 | 2010-02-17 | Microbia Inc | processos para produção de 4-bifenililazetidin-2-onas fenólicas |
| JP2008540573A (ja) * | 2005-05-13 | 2008-11-20 | マイクロビア インコーポレーテッド | ４−ビアリーリル−１−フェニラゼチジン−２−オン類 |
| AU2006249905A1 (en) * | 2005-05-25 | 2006-11-30 | Microbia, Inc. | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids |
| WO2006138163A2 (en) * | 2005-06-15 | 2006-12-28 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
| UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| ATE450526T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2008057948A2 (en) * | 2006-11-01 | 2008-05-15 | Ironwood Pharmaceuticals, Inc. | Processes for production of diphenylylazetidin-2-ones and related compounds |
| EP2086324A2 (en) * | 2006-11-02 | 2009-08-12 | Merck & Co., Inc. | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| JPWO2008108486A1 (ja) * | 2007-03-06 | 2010-06-17 | 帝人ファーマ株式会社 | １−ビアリールアゼチジノン誘導体 |
| US20080280836A1 (en) * | 2007-05-08 | 2008-11-13 | Morriello Gregori J | Anti-hypercholesterolemic biaryl azetidinone compounds |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2009126691A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| AU2011213072C1 (en) | 2010-02-03 | 2016-12-15 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| DK3362462T3 (da) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37721A (en) * | 1863-02-17 | Improvement in hose-couplings | ||
| ATE158789T1 (de) | 1991-07-23 | 1997-10-15 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| BR0116325A (pt) * | 2000-12-21 | 2003-10-14 | Aventis Pharma Gmbh | 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios |
| AU2002240050A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| ATE411018T1 (de) * | 2001-09-21 | 2008-10-15 | Schering Corp | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) |
| US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20070135357A1 (en) * | 2003-10-30 | 2007-06-14 | Sings Heather L | Anti-hypercholesterolemic compounds |
| EP1682499B1 (en) * | 2003-11-10 | 2007-08-08 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
| BRPI0608970A2 (pt) * | 2005-05-11 | 2010-02-17 | Microbia Inc | processos para produção de 4-bifenililazetidin-2-onas fenólicas |
| AU2006249905A1 (en) * | 2005-05-25 | 2006-11-30 | Microbia, Inc. | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US20080280836A1 (en) * | 2007-05-08 | 2008-11-13 | Morriello Gregori J | Anti-hypercholesterolemic biaryl azetidinone compounds |
-
2004
- 2004-11-10 EP EP04810780A patent/EP1682499B1/en not_active Expired - Lifetime
- 2004-11-10 PL PL04810780T patent/PL1682499T3/pl unknown
- 2004-11-10 AT AT04810780T patent/ATE369335T1/de not_active IP Right Cessation
- 2004-11-10 KR KR1020067011344A patent/KR20070050861A/ko not_active Ceased
- 2004-11-10 CA CA002545058A patent/CA2545058A1/en not_active Abandoned
- 2004-11-10 DK DK04810780T patent/DK1682499T3/da active
- 2004-11-10 PT PT04810780T patent/PT1682499E/pt unknown
- 2004-11-10 WO PCT/US2004/037715 patent/WO2005047248A1/en not_active Ceased
- 2004-11-10 MX MXPA06005106A patent/MXPA06005106A/es active IP Right Grant
- 2004-11-10 PL PL380414A patent/PL380414A1/pl not_active Application Discontinuation
- 2004-11-10 ES ES04810780T patent/ES2291974T3/es not_active Expired - Lifetime
- 2004-11-10 BR BRPI0416361-3A patent/BRPI0416361A/pt not_active IP Right Cessation
- 2004-11-10 AU AU2004288822A patent/AU2004288822A1/en not_active Abandoned
- 2004-11-10 US US10/986,570 patent/US7320972B2/en not_active Expired - Fee Related
- 2004-11-10 EA EA200600950A patent/EA010026B1/ru not_active IP Right Cessation
- 2004-11-10 JP JP2006539874A patent/JP2007520453A/ja active Pending
- 2004-11-10 NZ NZ546940A patent/NZ546940A/en unknown
- 2004-11-10 DE DE602004008100T patent/DE602004008100T2/de not_active Expired - Lifetime
-
2006
- 2006-05-04 IL IL175414A patent/IL175414A0/en unknown
- 2006-05-05 MA MA29006A patent/MA28216A1/fr unknown
- 2006-06-09 NO NO20062665A patent/NO20062665L/no not_active Application Discontinuation
-
2007
- 2007-11-08 CY CY20071101429T patent/CY1106982T1/el unknown
- 2007-12-11 US US11/954,170 patent/US20080167255A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004008100D1 (de) | 2007-09-20 |
| ATE369335T1 (de) | 2007-08-15 |
| US7320972B2 (en) | 2008-01-22 |
| EP1682499A1 (en) | 2006-07-26 |
| MXPA06005106A (es) | 2007-01-25 |
| JP2007520453A (ja) | 2007-07-26 |
| CY1106982T1 (el) | 2012-09-26 |
| IL175414A0 (en) | 2006-09-05 |
| ES2291974T3 (es) | 2008-03-01 |
| PL380414A1 (pl) | 2007-01-22 |
| DK1682499T3 (da) | 2008-01-02 |
| MA28216A1 (fr) | 2006-10-02 |
| NZ546940A (en) | 2008-11-28 |
| US20080167255A1 (en) | 2008-07-10 |
| DE602004008100T2 (de) | 2008-04-30 |
| EP1682499B1 (en) | 2007-08-08 |
| AU2004288822A1 (en) | 2005-05-26 |
| HK1093974A1 (en) | 2007-03-16 |
| EA200600950A1 (ru) | 2006-10-27 |
| CA2545058A1 (en) | 2005-05-26 |
| WO2005047248A1 (en) | 2005-05-26 |
| NO20062665L (no) | 2006-08-09 |
| BRPI0416361A (pt) | 2007-05-08 |
| PL1682499T3 (pl) | 2008-01-31 |
| PT1682499E (pt) | 2007-11-05 |
| US20050209165A1 (en) | 2005-09-22 |
| EA010026B1 (ru) | 2008-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070050861A (ko) | ４-비아릴일-１-페닐아제티딘-２-온 | |
| EP1362855B1 (en) | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same | |
| US20090131395A1 (en) | Biphenylazetidinone cholesterol absorption inhibitors | |
| US20080194494A1 (en) | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | |
| WO2005021497A2 (en) | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones | |
| WO2005021495A2 (en) | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones | |
| WO2008039829A2 (en) | Diphenylheterocycle cholesterol absorption inhibitors | |
| EP1885694A2 (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
| WO2006086562A2 (en) | Phenylazetidinone derivatives | |
| EP1879860A2 (en) | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia | |
| EP1934175B1 (en) | Anti-hypercholesterolemic compounds | |
| HK1116473A (en) | 4-biarylyl-1-phenolyzetidin-2-ones | |
| EP1832576A1 (en) | 4-Biarylyl-1-phenolyzetidin-2-ones | |
| HK1093974B (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
| CN1902169A (zh) | 4－联芳基－1－苯基氮杂环丁烷－2－酮 | |
| HK1060357B (en) | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060609 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20091028 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110513 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20120103 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110513 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |